The final decision regarding the split of Samsung Biologics' CDMO (Contract Development and Manufacturing Organization) and new drug development businesses will be made on October 17, 2025.
According to the pharmaceutical and biotech industry on August 22, Samsung Biologics announced that it will change the date of its shareholders' meeting to approve the spin-off plan from the originally scheduled September 16 to October 17.
Samsung Biologics initially planned to submit its securities registration statement on July 29, but the submission was delayed by about a month at the request of the Korea Exchange, resulting in the postponement of the shareholders' meeting. On August 21, the Korea Exchange KOSPI Market Division announced that Samsung Biologics had been deemed eligible in the preliminary review for the spin-off and relisting.
Due to the postponement of the shareholders' meeting, the scheduled establishment date for Samsung Episholdings, which will be created by spinning off the subsidiary management and new investment business segments of Samsung Biologics, has also been changed from October 1 to early November.
Since the revised spin-off date of November 1 falls on a Saturday, the actual establishment date is expected to be November 3, when the registration application is submitted.
The scheduled relisting date for the surviving company, Samsung Biologics, and the newly established Samsung Episholdings has been changed from October 29 to November 24. Samsung Episholdings will own Samsung Bioepis and any future newly established companies as 100% subsidiaries, while Samsung Biologics will be restructured to retain only Samsung Biologics America as its subsidiary.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
